The funds will be used by the Portland, Oregon-based startup to continue development on an advanced infusion set that combines continuous glucose monitoring (CGM) and insulin infusion in a single-port device. PDT has been refining a prototype in animal studies as it prepares to seek FDA approval to test the device in humans. In addition to the JDRF grant, PDT has secured more than $5 million in funding for the project from the National Institute of Diabetes and Digestive and Kidney Health and the Leona M. and Harry B. Helmsley Charitable Trust.
"JDRF is excited to partner with Pacific Diabetes Technologies to help advance infusion set technology that could improve the lives of people living with type 1 diabetes," said Vincent Crabtree, director of research business development at JDRF. "The T1D community is looking forward to advances in their CGM devices that can improve their ability to maintain glucose control safely and conveniently, and JDRF is committed to enabling that type of next-generation technology."